Halofantrine pharmacokinetics in Kenyan children with non-severe and severe malaria.

1. Kenyan children with uncomplicated malaria given oral halofantrine (HF; non-micronised suspension; 8 mg base kg-1 body weight 6 hourly for three doses) showed wide variation in the disposition of HF and desbutylhalofantrine (HFm). 2. Eight Kenyan children with severe (prostrate) falciparum malaria who were receiving intravenous quinine, were given the same HF regimen by nasogastric tube. One patient had undetectable HF and two had undetectable HFm at all times after drug administration. 3. The mean AUC(0,24 h) of HF in prostrate children was half (7.54 compared with 13.10 micrograms ml-1 h) (P = 0.06), and that for HFm one-third (0.84 compared with 2.51 micrograms ml-1 h) (P < 0.05) of the value in children with uncomplicated malaria. 4. Oral HF may be appropriate for some cases of uncomplicated falciparum malaria in Africa, but in patients with severe malaria, the bioavailability of HF and HFm may be inadequate.

[1]  J. Karbwang,et al.  Cardiac effect of halofantrine , 1993, The Lancet.

[2]  K. Marsh,et al.  Falciparum malaria: differential effects of antimalarial drugs on ex vivo parasite viability during the critical early phase of therapy. , 1993, The American journal of tropical medicine and hygiene.

[3]  H. Webster,et al.  Halofantrine versus mefloquine in treatment of multidrug-resistant falciparum malaria , 1993, The Lancet.

[4]  D. Kyle,et al.  Cardiac effects of antimalarial treatment with halofantrine , 1993, The Lancet.

[5]  R. Moyou,et al.  Fast emergence of Plasmodium falciparum resistance to halofantrine , 1993, The Lancet.

[6]  W. Watkins,et al.  Measurement of halofantrine and its major metabolite desbutylhalofantrine in plasma and blood by high-performance liquid chromatography: a new methodology. , 1992, Journal of chromatography.

[7]  K. Marsh,et al.  Malaria-a neglected disease? , 1992, Parasitology.

[8]  K. Marsh,et al.  Quinine treatment of severe falciparum malaria in African children: a randomized comparison of three regimens. , 1991, The American journal of tropical medicine and hygiene.

[9]  S. Ward,et al.  Measurement of quinine in filter paper-absorbed blood by high-performance liquid chromatography. , 1991, Journal of chromatography.

[10]  S. Ward,et al.  Pharmacokinetics of halofantrine in Thai patients with acute uncomplicated falciparum malaria. , 1991, British journal of clinical pharmacology.

[11]  P. Ringwald,et al.  Reduced in vitro susceptibility to halofantrine of Plasmodium falciparum in West Africa , 1990, The Lancet.

[12]  H. Eichenwald CHLOROQUINE TREATMENT OF SEVERE MALARIA IN CHILDREN: PHARMACOKINETICS, TOXICITY, AND NEW DOSAGE RECOMMENDATIONS , 1989 .

[13]  A. Breckenridge,et al.  Pharmacokinetics of halofantrine in man: effects of food and dose size. , 1989, British journal of clinical pharmacology.

[14]  K. Miller,et al.  Chloroquine treatment of severe malaria in children. Pharmacokinetics, toxicity, and new dosage recommendations. , 1988, The New England journal of medicine.

[15]  D. Kariuki,et al.  EFFICACY OF MULTIPLE-DOSE HALOFANTRINE IN TREATMENT OF CHLOROQUINE-RESISTANT FALCIPARUM MALARIA IN CHILDREN IN KENYA , 1988, The Lancet.

[16]  D. Warrell,et al.  Pathophysiology of severe falciparum malaria. , 1992, Papua and New Guinea medical journal.

[17]  N. White,et al.  Intragastric mefloquine is absorbed rapidly in patients with cerebral malaria. , 1985, The American journal of tropical medicine and hygiene.

[18]  L. Sax,et al.  DRUG SENSITIVITY OF PLASMODIUM FALCIPARUM An In-vitro Microtechnique , 1978, The Lancet.